MicroRNA‑367‑3p induces apoptosis and suppresses migration of MCF‑7 cells by downregulating the expression of human choline kinase α

Raikundalia,Sweta; Mohamed Sa'dom,Siti Aisyah Faten; Few,Ling Ling; See Too,Wei Cun

doi:10.3892/ol.2021.12444

MicroRNA‑367‑3p induces apoptosis and suppresses migration of MCF‑7 cells by downregulating the expression of human choline kinase α

Authors:
- Sweta Raikundalia
- Siti Aisyah Faten Mohamed Sa'dom
- Ling Ling Few
- Wei Cun See Too
View Affiliations

Affiliations: School of Health Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia
Published online on: January 6, 2021 https://doi.org/10.3892/ol.2021.12444
Article Number: 183
Copyright: © Raikundalia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Choline kinase (ChK) catalyzes the first step in the CDP‑choline pathway for the synthesis of phosphatidylcholine. The α isoform of this enzyme is overexpressed in various types of cancer and its inhibition or downregulation has been applied as an anticancer strategy. In spite of increasing attention being paid to ChK expression, as well as its activity and inhibition in cancer, there are only limited studies available on the regulation of ChK, including its regulation by microRNAs (miRNAs/miRs). The dysregulation of gene expression by miRNAs is a common cause for carcinogenesis. In the present study, miR‑367‑3p was predicted to target the 3'‑untranslated region (UTR) of the ChK α (chka) mRNA transcript. The binding of miR‑367‑3p to the 3'‑UTR of chka was validated by a luciferase assay. The effects of the miR‑367‑3p mimic on chka gene and protein expression levels were determined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. miR‑367‑3p significantly downregulated the expression of chka to ~60% of the negative control. Cells transfected with miR‑367‑3p exhibited higher levels of apoptosis and a lower cell migration compared with the control. To the best of our knowledge, the present study provided the first experimental evidence of the regulation of chka expression by miR‑367‑3p. The pro‑apoptotic and suppressive effects of miR‑367‑3p on cell migration were similar to the anticancer effects resulting from the inhibition of ChK enzyme activity or the knockdown of chka gene expression by small interfering RNA. Therefore, these findings may potentially lead to the use of miR‑367‑3p in anticancer strategies that target ChK.

View Figures

View References

1	Arlauckas SP, Popov AV and Delikatny EJ: Choline kinase alpha-putting the choK-hold on tumor metabolism. Prog Lipid Res. 63:28–40. 2016. View Article : Google Scholar : PubMed/NCBI
2	Sanchez-Lopez E, Zimmerman T, Gomez del Pulgar T, Moyer MP, Lacal Sanjuan JC and Cebrian A: Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death Dis. 4:e9332013. View Article : Google Scholar : PubMed/NCBI
3	Chang CC, Few LL, Konrad M and See Too WC: Phosphorylation of human choline kinase beta by protein kinase A: Its impact on activity and inhibition. PLoS One. 11:e01547022016. View Article : Google Scholar : PubMed/NCBI
4	Gruber J, See Too WC, Wong MT, Lavie A, McSorley T and Konrad M: Balance of human choline kinase isoforms is critical for cell cycle regulation: Implications for the development of choline kinase-targeted cancer therapy. FEBS J. 279:1915–1928. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wu G and Vance DE: Choline kinase and its function. Biochem Cell Biol. 88:559–564. 2010. View Article : Google Scholar : PubMed/NCBI
6	Gómez-Pérez V, McSorley T, See Too WC, Konrad M and Campos JM: Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line. ChemMedChem. 7:663–669. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gebert LFR and MacRae IJ: Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 20:21–37. 2019. View Article : Google Scholar : PubMed/NCBI
8	Hirschberger S, Hinske LC and Kreth S: miRNAs: Dynamic regulators of immune cell functions in inflammation and cancer. Cancer Lett. 431:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
9	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
10	Xu H, Hu YW, Zhao JY, Hu XM, Li SF, Wang YC, Gao JJ, Sha YH, Kang CM, Lin L, et al: MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma. Oncol Rep. 34:175–182. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhao X, Dou W, He L, Liang S, Tie J, Liu C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372. 2013. View Article : Google Scholar : PubMed/NCBI
12	Bueno MJ, Gómez de Cedrón M, Gómez-López G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martínez N, Guerrero M, Sánchez-Martínez R, Santos J, et al: Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood. 117:6255–6266. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG and Slack FJ: A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 34:3547–3555. 2015. View Article : Google Scholar : PubMed/NCBI
14	van Rooij E, Purcell AL and Levin AA: Developing microRNA therapeutics. Circ Res. 110:496–507. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chakraborty C, Sharma AR, Sharma G, George C, Doss CGP and Lee SS: Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acid. 8:132–143. 2017. View Article : Google Scholar
16	Broderick JA and Zamore PD: MicroRNA therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
17	Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI
18	Lorenz WA and Clote P: Computing the partition function for kinetically trapped RNA secondary structures. PLoS One. 6:e161782011. View Article : Google Scholar : PubMed/NCBI
19	Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
20	Xayaphoummine A, Bucher T and Isambert H: Kinefold web server for RNA/DNA folding path and structure prediction including pseudoknots and knots. Nucleic Acids Res. 33:(Web Server Issue). W605–W610. 2005. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
23	Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M and Mezzanzanica D: Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer. 110:330–340. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mariotto E, Viola G, Ronca R, Persano L, Aveic S, Bhujwalla ZM, Mori N, Accordi B, Serafin V, López-Cara LC and Bortolozzi R: Choline kinase alpha inhibition by EB-3D triggers cellular senescence, reduces tumor growth and metastatic dissemination in breast cancer. Cancers (Basel). 10:3912018. View Article : Google Scholar
25	Oliveira AC, Bovolenta LA, Nachtigall PG, Herkenhoff ME, Lemke N and Pinhal D: Combining results from distinct MicroRNA target prediction tools enhances the performance of analyses. Front Genet. 8:592017. View Article : Google Scholar : PubMed/NCBI
26	Zheng Z, Reichel M, Deveson I, Wong G, Li J and Millar AA: Target RNA secondary structure is a major determinant of miR159 efficacy. Plant Physiol. 174:1764–1778. 2017. View Article : Google Scholar : PubMed/NCBI
27	Rosa A and Brivanlou AH: Regulatory non-coding RNAs in pluripotent stem cells. Int J Mol Sci. 14:14346–14373. 2013. View Article : Google Scholar : PubMed/NCBI
28	Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, Cai X and Chang C: The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals. EBioMedicine. 12:55–67. 2016. View Article : Google Scholar : PubMed/NCBI
29	Xiao G, Gao X, Sun X, Yang C, Zhang B, Sun R, Huang G, Li X, Liu J, Du N, et al: miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC. Oncol Rep. 38:1190–1198. 2017. View Article : Google Scholar : PubMed/NCBI
30	Yan W, Jiang X, Wang G, Li W, Zhai C, Chen S, Shang F, Zhao Z and Yu W: Cyto-biological effects of microRNA-424-5p on human colorectal cancer cells. Oncol Lett. 20:1202020. View Article : Google Scholar : PubMed/NCBI
31	Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, et al: Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 31:376–383. 2014. View Article : Google Scholar : PubMed/NCBI
32	Bin Z, Dedong H, Xiangjie F, Hongwei X and Qinghui Y: The microRNA-367 inhibits the invasion and metastasis of gastric cancer by directly repressing Rab23. Genet Test Mol Biomarkers. 19:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
33	Guan Y, Chen L, Bao Y, Qiu B, Pang C, Cui R and Wang Y: High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma. Int J Clin Exp Pathol. 8:6576–6588. 2015.PubMed/NCBI
34	Campayo M, Navarro A, Vinõlas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M and Marrades R: Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J. 41:1172–1178. 2013. View Article : Google Scholar : PubMed/NCBI
35	Zhu Z, Xu Y, Zhao J, Liu Q, Feng W, Fan J and Wang P: miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway. Br J Cancer. 112:1367–1375. 2015. View Article : Google Scholar : PubMed/NCBI
36	Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
37	Li C, Penet MF, Wildes F, Takagi T, Chen Z, Winnard PT, Artemov D and Bhujwalla ZM: Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano. 4:6707–6716. 2010. View Article : Google Scholar : PubMed/NCBI
38	Chen Z, Krishnamachary B and Bhujwalla ZM: Degradable dextran nanopolymer as a carrier for choline kinase (Chok) siRNA cancer therapy. Nanomaterials (Basel). 6:342016. View Article : Google Scholar
39	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
40	Falcon SC, Hudson CS, Huang Y, Mortimore M, Golec JM, Charlton PA, Weber P and Sundaram H: A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival. Oncogenesis. 2:e382013. View Article : Google Scholar : PubMed/NCBI